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Antibodies specific to the attachment protein of Mycoplasma pneumoniae were
demonstrated in sera and respiratory secretions of human patients. The results
indicate that the attachment protein is a major immunogen.
Mycoplasma pneumoniae is one of the most
common causes of human respiratory tract in-
fections (6) and is the principal etiological agent
of atypical pneumonia. It has been recognized
for some time that M. pneumoniae, as well as
other mycoplasma species, can attach firmly to
various types of epithelium cells (16). Previous
studies have indicated that attachment of M.
pneumoniae to host respiratory epithelium is
mediated through a specialized structure at one
end of this filamentous organism (4, 5). Subse-
quently, we have demonstrated that a surface
protein component, designated as P1 protein, is
involved in this attachment process (10). Re-
cently, we have provided direct evidence that P1
protein is localized at the surface of the terminal
organelle of M. pneumoniae by using monoclon-
al antibodies specific for Pl protein (9). This
observation was subsequently confirmed by
Feldner et al. (7) and Baseman et al. (1), who
used monoclonal antibody and monospecific
antibody, respectively, against P1 protein. Base-
man et al. claimed that the Pl protein, although
mainly concentrated over the terminal structure,
might also be scattered over other parts of the
surface of M. pneumoniae. Despite this minor
discrepancy, the importance of P1 in the patho-
genesis of M. pneumoniae infection is now con-
sidered established.
The role of the humoral immune response in
protection against M. pneumoniae infection has
been well documented (13, 17), and surface
proteins of M. pneumoniae, including P1 pro-
tein, have been suggested as possible vaccine
candidates (8). To investigate this possibility, we
conducted experiments to study the immunoge-
nicity of the constituent proteins of M. pneumo-
niae. When Western blot transfer was combined
with a radioimmunobinding assay (11), antibod-
ies to seven immunogens, including P1 protein,
were found in the sera of hamsters infected with
M. pneumoniae by inhalation. We found that
many more proteins were capable of stimulating
antibodies in rabbits immunized parenterally
with mycoplasmas. The present study extends
this technique to human sera and respiratory
secretions to ensure that P1 and other M. pneu-
moniae proteins are also immunogenic for hu-
mans.
M. pneumoniae M129 (ATCC 29342), was
used in this study. Cultures were maintained in
Hayflick medium supplemented with 20% agam-
maglobulin horse serum, 10% yeast dialysate,
and penicillin (1,000 U/ml) (10). Monolayer cul-
tures were grown in glass prescription bottles.
After incubation at 37°C for 36 to 48 h, the
medium was decanted, and the organisms were
rinsed three times with phosphate-buffered sa-
line (pH 7.2). The organisms were then scraped
into the phosphate-buffered saline, pelleted by
centrifugation (12,000 x g for 15 min), and
processed for sodium dodecyl sulfate-polyacryl-
amide gel electrophoresis.
Electrophoresis of M. pneumoniae proteins
on sodium dodecyl sulfate-polyacrylamide
(10%) and Western blot transfer were the same
as described previously (9). After transfer, the
nitrocellulose blots were incubated with sera or
respiratory secretions from human patients with
culture-proven M. pneumoniae infection and
then imaged with "251-labeled goat anti-human
immunoglobulin G (IgG), IgM, or secretory IgA
(Cappel Laboratories, Cochranville, Pa.). Ra-
dioautographs were produced with Xomat-AR5
film (Kodak) at -80°C for 12 to 24 h with an
intensifying screen (DuPont Co., Wilmington,
Del.).
A total of 12 paired (acute and convalescent)
serum samples were examined. Representative
data are presented in Fig. 1. Despite marked
variations in each individual's ability to recog-
nize and respond to different mycoplasma anti-
gens, all patients with high complement fixation
or radioimmunoassay titers (Table 1) reacted
with Pl protein (molecular weight, 190,000) and



















FIG. 1. Demonstration of antibodies to M. pneu-
moniae attachment protein (P1) in human sera. (A) A
nitrocellulose blot was incubated with a monoclonal
antibody (M128) which has been shown to be specific
to P1 protein (9), followed by incubation with 1251_
labeled rabbit anti-mouse IgG. (B to F) Nitrocellulose
blots were incubated with paired acute and convales-
cent sera obtained from five patients and imaged with
125I-labeled goat anti-human IgG. Antibodies specific
to P1 protein were demonstrated in all sera tested,
indicating that it is a major immunogen in natural M.
pneumoniae infection. Molecular weights were deter-
mined by coelectrophoresis of protein standards with
known molecular weights.
Complement fixation titers were determined by
procedures previously described by Kenny and
Grayston (12). The solid-phase radio-
immunoassay was developed in our laboratory,
and details will be published elsewhere (P. C.
Hu, D. A. Powell, F. Albright, D. E. Gardner,
TABLE 1. Complement fixation and
radioimmunoassay titers in human mycoplasmal
pneumonia sera
Patient Date Comple- Radio-
code' serum ment fixa- immunoas-code" obtained tion titer say titer
B 10-06-79 2 7,663
10-31-79 128 25,850
C Pre 4 3,421
08-20-80 256 27,336
D 10-20-80 8 12,296
11-01-80 32 12,219
E 11-19-80 <2 4,060
12-05-80 512 28,520
F 12-04-80 8 12,197
01-07-81 64 19,886
a Patient designations correspond to the letters in
Fig. 1.
b The technical details of the radioimmunoassay
have been described elsewhere (P. C. Hu, D. A.
Powell, F. Albright, D. E. Gardner, A. M. Collier,
W. A. Clyde, Jr., J. Clin. Lab. Immunol., in press).
A. M. Collier, and W. A. Clyde, Jr., J. Clin. Lab.
Immunol., in press). These results are consistent
with our previous observations in infected ani-
mals (9) that Pl protein is a major immunogen.
The role of the 88,000-dalton protein is not
known at the present time.
Although Taylor and Taylor-Robinson (16)
have shown that colonization of Mycoplasma
pulmonis in the mouse respiratory tract could be
suppressed by systemic antibody, it has been
thought that local immune mechanisms, includ-
ing antibodies in the lung, may play a more
important role in the prevention of M. pneumo-
niae disease (2, 3). Biberfeld and Sterner (2)
used an indirect immunofluorescence test to
detect M. pneumoniae antibody in sputum sam-
ples. IgA antibodies were present in all 31 sam-
ples with detectable antimycoplasma activity:
IgG antibodies were present in 24 samples, IgM
in 13 samples. Local synthesis of secretory IgA
and transudation of serum antibodies into bron-
chial secretions were thought to be the source of
M. pneumoniae antibodies found in respiratory
tract secretions. To evaluate the role of P1
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FIG. 2. Demonstration of antibodies to M. pneu-
moniae attachment protein (Pl) in human respiratory
secretions. Nitrocellulose blots were incubated with
human sputa or nasal wash and imaged with 1251_
labeled goat anti-human IgG (A) or secretory IgA (B).
1, Nasal wash from a patient diagnosed with a negative
mycoplasma infection; 2 and 3, sputum samples from
patients with culture-proven M. pneumoniae infec-
tion; 4, nasal wash from a noninfected but heavily
exposed laboratory investigator (P.C.H.). Results in-
dicate that both IgG and secretory IgA antibodies




























protein as an immunogen in the respiratory
tract, respiratory secretions were examined for
the presence of antibodies specific to Pl protein.
As shown in Fig. 2, both IgG and secretory IgA
specific for P1 protein could be observed in
either sputum or nasal washes from all subjects
examined. It is possible that antibodies specific
to Pl protein may play a role(s) other than that
of antiattachment in the respiratory tract (7).
Powell and Clyde (16) reported that phagocyto-
sis of M. pneumoniae by alveolar macrophages
can be greatly enhanced by specific antibodies.
In addition, monoclonal antibodies specific to Pl
protein have been shown to inhibit the hemab-
sorption activity and motility of M. pneumoniae
(7).
In conclusion, the present studies have dem-
onstrated that patients with natural infection
uniformly react to the attachment protein of M.
pneumoniae by producing antibodies against it
in their blood and respiratory secretions. Identi-
fication of this surface protein, which stimulates
immunity, suggests the possibility of its use as a
vaccine to prevent M. pneumoniae disease.
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